Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Redeye Fight Cancer (January 2022)
10 slides from Cantargia Ab's conference presentation, January 2022
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Göran Forsberg, CEO Jan 2022 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia: the IL1RAP company
Cantargia: the IL1RAP company FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET • Five Phase I/II trials, with positive interim data in pancreatic cancer and NSCLC • Differentiated by broad MOA and unique binding properties • Synergistic with established therapies PLATFORM WITH BROAD POT
Slide 4: IL1RAP is overexpressed in most solid tumors
IL1RAP is overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES IL1RAP-EXPRESSING CELLS IN TUMOR MICROENVIRONMENT IL1RAP-expressing tumors 100 75 50 25 0 l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer cell surface Stroma IL1RAP: DI
Slide 5: Cantargia – Save lives and create value through IL1RAP
Cantargia – Save lives and create value through IL1RAP Potentially more effective treatment against novel target in clinically validated pathway First in class platform technology against novel target Well financed to build a broad, diversified pipeline Right team and clear plan to position our proj
Slide 6: Advancing PDAC development to phase 2/3
Advancing PDAC development to phase 2/3 PanCAN’s Precision Promise adaptive clinical trial platform designed together with FDA Nadunolimab selected for inclusion → 15 leading US clinical centers - additional sites planned → Patients randomized to receive nadunolimab with gemcitabine and nab-paclitax
Slide 7: Positive interim data in pancreatic cancer
Positive interim data in pancreatic cancer Nadunolimab combination with Gem/Abraxane in 1st line (Dec 2021), n=33: → 27% response rate with durable responses, two patients still on treatment → Pseudoprogression-like response in 5 (15%) patients predict long PFS → Promising PFS (7.2 mo) and OS (12.7
Slide 8: Safety profile is manageable and supports MOA
Safety profile is manageable and supports MOA CANFOUR Gem/Abraxane FOLFIRINOX Nadunolimab/ Grade 3 or higher AEs (von Hoff) (Conroy 2011) Gem/Abraxane N=421 N=171 N=36 Neutropenia 38% 67% 46% → G-CSF is an approved therapy to counteract neutropenia; G-CSF Febrile neutropenia 3% 17% 5% w
Slide 9: Combination strategy in NSCLC – Promising efficacy
Combination strategy in NSCLC – Promising efficacy Nadunolimab combination with Gem/Cis in 1st line chemotherapy: → 13 of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (ORR 48% vs historical control data of 22-28%) → No m
Slide 10: Cantargia – Save lives and create value through IL1RAP
Cantargia – Save lives and create value through IL1RAP LARGE NUMBER OF CLINICAL MILESTONES DURING 2022 BASED ON INITIAL RESULTS, MOST PROMISING OPPORTUNITIES TO BE EXPANDED 10